Why "PDA" entered the market when it did In November 2023, the FDA added BPC-157 to its list of bulk drug substances that may present significant safety risks under Section 503A compounding
For spinal applications specifically, animal studies have examined BPC-157s effects on nerve injuries and demonstrated protective and regenerative effects
Clinical Indicators for Coders/CDI The following indicators, when present in physician documentation, laboratory values, or diagnostic reports, support assignment of a Crohns disease diagnosis and may trigger CDI queries for greater specificity: When imaging or operative reports document a fistula, abscess, or bowel obstruction in a patient with known Crohns disease, and the attendings Crohns diagnosis code lacks a complication specifier, query the provider: Does the patients current admission involve Crohns disease with [fistula / abscess / obstruction / rectal bleeding] as a complication of the Crohns, a separate condition, or both? This distinction determines whether to code K50.x13, K50.x14, K50.x12, or K50.x11 vs
Drop back to the previous dose and attempt escalation again after an additional 2-4 weeks
